WO2005070454A3 - A novel process of hepatitis a vaccine preparation - Google Patents

A novel process of hepatitis a vaccine preparation Download PDF

Info

Publication number
WO2005070454A3
WO2005070454A3 PCT/IN2005/000020 IN2005000020W WO2005070454A3 WO 2005070454 A3 WO2005070454 A3 WO 2005070454A3 IN 2005000020 W IN2005000020 W IN 2005000020W WO 2005070454 A3 WO2005070454 A3 WO 2005070454A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus
vaccine preparation
mrc
vero
Prior art date
Application number
PCT/IN2005/000020
Other languages
French (fr)
Other versions
WO2005070454A2 (en
Inventor
Shobha Dattatraya Chitamber
Akundi Poorna Kalanidhi
Original Assignee
Bharat Biotech Int Ltd
Nat Inst Of Virology
Shobha Dattatraya Chitamber
Akundi Poorna Kalanidhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd, Nat Inst Of Virology, Shobha Dattatraya Chitamber, Akundi Poorna Kalanidhi filed Critical Bharat Biotech Int Ltd
Priority to EP05709163A priority Critical patent/EP1709162A2/en
Publication of WO2005070454A2 publication Critical patent/WO2005070454A2/en
Publication of WO2005070454A3 publication Critical patent/WO2005070454A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32463—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An Indian isolate of Hepatitis A virus- NIVIN97 has been isolated, adapted to tissue culture, characterized and further propagated using Vero and MRC-5 cell lines for vaccine preparation. The method involves the cell culture adaptation of the virus isolate from clinical sample (faecal) in BGMK cell line initially , characterization of the virus and further adaptation to Vero and MRC-5 cells , scale-up ,inactivation and down stream processing method of the inactivated viral antigens for the preparation of an inactivated vaccine.
PCT/IN2005/000020 2004-01-27 2005-01-19 A novel process of hepatitis a vaccine preparation WO2005070454A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05709163A EP1709162A2 (en) 2004-01-27 2005-01-19 A novel process of hepatitis a vaccine preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN60/CHE/2004 2004-01-27
IN60CH2004 2004-01-27

Publications (2)

Publication Number Publication Date
WO2005070454A2 WO2005070454A2 (en) 2005-08-04
WO2005070454A3 true WO2005070454A3 (en) 2005-11-03

Family

ID=34803677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000020 WO2005070454A2 (en) 2004-01-27 2005-01-19 A novel process of hepatitis a vaccine preparation

Country Status (2)

Country Link
EP (1) EP1709162A2 (en)
WO (1) WO2005070454A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101816786B (en) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 Inactivated hepatitis A vaccine and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583142A2 (en) * 1992-08-07 1994-02-16 Merck & Co. Inc. Hepatitis A virus vaccine
US5549896A (en) * 1991-05-08 1996-08-27 Schweiz. Serum- & Impfinstitut Bern Hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines
WO2000023574A2 (en) * 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Hepatitis a vaccines
WO2003049766A2 (en) * 2001-12-10 2003-06-19 Baxter Healthcare S.A. Method of purifying hepatitis a virus particles and vaccine preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549896A (en) * 1991-05-08 1996-08-27 Schweiz. Serum- & Impfinstitut Bern Hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines
EP0583142A2 (en) * 1992-08-07 1994-02-16 Merck & Co. Inc. Hepatitis A virus vaccine
WO2000023574A2 (en) * 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Hepatitis a vaccines
WO2003049766A2 (en) * 2001-12-10 2003-06-19 Baxter Healthcare S.A. Method of purifying hepatitis a virus particles and vaccine preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDRE F E ET AL: "INACTIVATED CANDIDATE VACCINES FOR HEPATITIS A", PROGRESS IN MEDICAL VIROLOGY, KARGER, BASEL, CH, vol. 37, no. 1, 1990, pages 72 - 95, XP000904877, ISSN: 0079-645X *
KOFF R S: "Hepatitis A", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 351, no. 9116, 30 May 1998 (1998-05-30), pages 1643 - 1649, XP004833427, ISSN: 0140-6736 *
VAIDYA SUNIL R ET AL: "Polymerase chain reaction-based prevalence of hepatitis A, hepatitis E and TT viruses in sewage from an endemic area.", JOURNAL OF HEPATOLOGY, vol. 37, no. 1, July 2002 (2002-07-01), pages 131 - 136, XP002340517, ISSN: 0168-8278 *

Also Published As

Publication number Publication date
WO2005070454A2 (en) 2005-08-04
EP1709162A2 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
Oka et al. Cell culture isolation and sequence analysis of genetically diverse US porcine epidemic diarrhea virus strains including a novel strain with a large deletion in the spike gene
Liu et al. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
CN105412153B (en) Application of the excretion body of mescenchymal stem cell secretion in preparation prevention and treatment hepatitis C virus cytotoxic drug
JP4370511B2 (en) Large-scale generation method of viral antigen
ES2536745T3 (en) Methods of production of influenza vaccine compositions
Roner et al. Reovirus RNA is infectious
EP1108787A3 (en) Production of vaccines
HRP20140375T1 (en) Method for producing viral vaccines
WO2006071563A3 (en) Non-tumorigenic mdck cell line for propagating viruses
CN111330002A (en) General DC cell vaccine of targeted coronavirus, preparation method and application thereof
CN110747175B (en) Pig delta coronavirus and application thereof
JP2013515473A5 (en)
EP2716752A1 (en) Canine influenza recombinant virus, preparation method therefor and application thereof
US10407667B2 (en) Method for rapid generation of an infectious RNA virus
CN107298700B (en) Artificially-modified PCV2Rep protein, recombinant PCV2 virus and application thereof
WO2005070454A3 (en) A novel process of hepatitis a vaccine preparation
WO2000023574A3 (en) Hepatitis a vaccines
Cheung et al. Production of single‐cycle infectious SARS‐CoV‐2 through a trans‐complemented replicon
WO2003049767A3 (en) Method of large scale production of hepatitis a virus
CN108055827B (en) High-growth enterovirus 71 type virus strain and vaccine thereof
CN114349829A (en) Identification of ALV-J MHC-B2 restricted epitope peptide and application thereof
MX2012002702A (en) Bovine herpesvirus vaccine.
CN107723279B (en) Culture method of defective adenovirus AdC68-GP
KR101581228B1 (en) - two-step temperature profile for the propagation of viruses
US10208291B2 (en) Method for generating high-titer hepatitis E virus stocks and titration assay for hepatitis E virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005709163

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005709163

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005709163

Country of ref document: EP